[{"address1": "2 Corporate Drive", "address2": "First Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 239 2030", "website": "https://www.sentibio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder, CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 868569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kanya  Rajangam M.D., Ph.D.", "age": 49, "title": "President, Head of Research & Development and Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 689991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 58500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wilson  Wong Ph.D.", "title": "Scientific Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Li M.B.A.", "age": 63, "title": "Interim CFO, Treasurer & Principal Accounting Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Rhee", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas P. Chung", "title": "Vice President of Strategic Finance & Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dee Olomajeye Dragon", "title": "Vice President of People Strategy & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.276, "open": 0.3575, "dayLow": 0.3299, "dayHigh": 0.61, "regularMarketPreviousClose": 0.276, "regularMarketOpen": 0.3575, "regularMarketDayLow": 0.3299, "regularMarketDayHigh": 0.61, "beta": 2.784, "forwardPE": -0.5566667, "volume": 385924772, "regularMarketVolume": 385924772, "averageVolume": 884316, "averageVolume10days": 4771280, "averageDailyVolume10Day": 4771280, "bid": 0.2152, "ask": 0.61, "bidSize": 20000, "askSize": 100, "marketCap": 19102712, "fiftyTwoWeekLow": 0.211, "fiftyTwoWeekHigh": 1.09, "priceToSalesTrailing12Months": 14.982519, "fiftyDayAverage": 0.31824, "twoHundredDayAverage": 0.39303, "currency": "USD", "enterpriseValue": 25536386, "floatShares": 29164708, "sharesOutstanding": 45755000, "sharesShort": 270712, "sharesShortPriorMonth": 281367, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0058999998, "heldPercentInsiders": 0.21021, "heldPercentInstitutions": 0.24048, "shortRatio": 2.3, "shortPercentOfFloat": 0.0075, "impliedSharesOutstanding": 45755000, "bookValue": 1.227, "priceToBook": 0.3402608, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -81665000, "trailingEps": -1.83, "forwardEps": -0.75, "enterpriseToRevenue": 20.029, "enterpriseToEbitda": -0.424, "52WeekChange": -0.572093, "SandP52WeekChange": 0.22553468, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNTI", "underlyingSymbol": "SNTI", "shortName": "Senti Biosciences, Inc.", "longName": "Senti Biosciences, Inc.", "firstTradeDateEpochUtc": 1622035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6e1c0497-dfb2-3427-8088-6f54c5e467cc", "messageBoardId": "finmb_538838857", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4175, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 23815000, "totalCashPerShare": 0.52, "ebitda": -60240000, "totalDebt": 36723000, "quickRatio": 4.344, "currentRatio": 5.793, "totalRevenue": 1275000, "debtToEquity": 65.467, "revenuePerShare": 0.028, "returnOnAssets": -0.30499, "returnOnEquity": -0.96970004, "freeCashflow": -64550752, "operatingCashflow": -47773000, "operatingMargins": -50.445488, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-01"}]